Genocea to Present at the 16th Annual Needham Healthcare Conference
March 29 2017 - 8:00AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing T cell-directed vaccines and immunotherapies,
today announced that Chip Clark, president and chief executive
officer, will present a company overview at the 16th Annual Needham
Healthcare Conference on Wednesday, April 5, 2017 at 9:20 a.m. ET
in New York City.
A webcast replay will be available on the Genocea website
beginning approximately two hours after the event, and will be
archived for 30 days.
About Genocea Biosciences Inc.Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. T cells are increasingly recognized
as a critical element of protective immune responses to a wide
range of diseases, but traditional discovery methods have proven
unable to identify the targets of such protective immunity. Using
ATLASTM, its proprietary technology platform, Genocea identifies
these targets to potentially enable the rapid development of
medicines to address critical patient needs. Genocea’s pipeline
includes GEN-003, a novel T cell-enabled immunotherapy for genital
herpes currently in Phase 2 clinical development, and earlier-stage
investments in immuno-oncology. For more information, please visit
the company's website at www.genocea.com.
For media:
Jennifer LaVin
O: 617-715-6687
jennifer.lavin@genocea.com
For investors:
Jonathan Poole
O: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024